Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05687851 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2024 to Dec 30, 2024v2 Show 4 more changesShow less
    • Interventions: BT (Radiation), Candonilimab（AK104） (Drug), EBRT (Radiation) to BT (Radiation), Cadonilimab（AK104） (Drug), EBRT (Radiation)
    • Eligibility criteria revised
    • Collaborators: 1 to 3
    • Study title revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Trial Details
NCT Number NCT05687851
Lead Sponsor Chongqing University Cancer Hospital
Collaborators: Liaoning Cancer Hospital & Institute, Henan Cancer Hospital, Fujian Cancer Hospital
Conditions
(from sponsor)		 Locally Advanced Cervical Cancer
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov